Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $847,260.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $235.35, for a total value of $847,260.00. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $30,595.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $262.40 on Friday. United Therapeutics Co. has a 1 year low of $204.44 and a 1 year high of $262.51. The firm has a market capitalization of $11.64 billion, a price-to-earnings ratio of 12.41 and a beta of 0.54. The company has a current ratio of 4.41, a quick ratio of 4.28 and a debt-to-equity ratio of 0.05. The firm’s 50 day simple moving average is $236.15 and its 200 day simple moving average is $229.20.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, beating analysts’ consensus estimates of $5.63 by $0.54. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The firm had revenue of $677.70 million for the quarter, compared to the consensus estimate of $620.31 million. During the same quarter last year, the business posted $4.86 EPS. The company’s revenue was up 33.7% compared to the same quarter last year. As a group, research analysts expect that United Therapeutics Co. will post 23.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in shares of United Therapeutics by 0.4% in the third quarter. Vanguard Group Inc. now owns 4,662,911 shares of the biotechnology company’s stock worth $1,053,212,000 after acquiring an additional 20,373 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of United Therapeutics by 1.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 561,950 shares of the biotechnology company’s stock worth $123,566,000 after buying an additional 9,962 shares during the last quarter. Norges Bank bought a new stake in shares of United Therapeutics during the fourth quarter worth $100,519,000. LSV Asset Management increased its holdings in shares of United Therapeutics by 1.0% during the third quarter. LSV Asset Management now owns 383,068 shares of the biotechnology company’s stock worth $86,524,000 after buying an additional 3,700 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of United Therapeutics by 2.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 319,030 shares of the biotechnology company’s stock valued at $70,152,000 after acquiring an additional 7,723 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Leerink Partnrs restated an “outperform” rating on shares of United Therapeutics in a report on Monday, February 5th. SVB Leerink initiated coverage on shares of United Therapeutics in a research note on Monday, February 5th. They set an “outperform” rating and a $330.00 price objective on the stock. Wedbush reiterated an “outperform” rating and issued a $308.00 target price on shares of United Therapeutics in a research note on Thursday, February 22nd. Wells Fargo & Company boosted their price target on United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a research report on Thursday, March 7th. Finally, HC Wainwright restated a “buy” rating and issued a $300.00 price objective on shares of United Therapeutics in a research note on Thursday. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $308.78.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.